Cadrenal Therapeutics, Inc. 8-K

What Happened
Cadrenal Therapeutics, Inc. filed a prospectus supplement with the SEC on December 23, 2025 to offer up to $1,770,028 of its common stock under its existing at-the-market (ATM) offering program. The sales will be made through H.C. Wainwright & Co., LLC under the ATM Agreement dated March 11, 2024, and the offering is made pursuant to the company’s effective Form S-3 registration statement (File No. 333-277835). To date, Cadrenal has sold $10,005,300 of common stock under the ATM program.

Key Details

• Prospectus supplement filed: December 23, 2025.
• Amount available under this supplement: up to $1,770,028 of common stock.
• Sales agent: H.C. Wainwright & Co., LLC (ATM Agreement dated March 11, 2024).
• Fees: Wainwright receives 3.0% of the gross sales price on shares sold through the ATM.
• Registration: Offering made under Form S-3 (File No. 333-277835), declared effective March 20, 2024.
• Shares sold to date under ATM: $10,005,300.
• Legal: Blank Rome LLP provided an opinion on the validity of the shares (filed as Exhibit 5.1).

Why It Matters
This filing signals Cadrenal is using its ATM facility to raise capital incrementally and has added up to $1.77 million available to sell into the market. For investors, ATM sales can dilute existing shareholders depending on the number and timing of shares sold, but they provide the company with flexible, on‑demand access to cash without a single large offering. The 3% sales commission and the company’s prior ATM sales ($10.0M) are concrete costs and activity metrics to watch as they reflect how aggressively management is accessing equity capital.